Safety pharmacology — Current and emerging concepts

Journal Article · Sun Dec 01 00:00:00 EST 2013 · Toxicology and Applied Pharmacology

DOI:https://doi.org/10.1016/J.TAAP.2013.04.039· OSTI ID:22285504

Hamdam, Junnat; Sethu, Swaminathan; Smith, Trevor; Alfirevic, Ana; Alhaidari, Mohammad ^[1]; Atkinson, Jeffrey ^[2]; Ayala, Mimieveshiofuo; Box, Helen; Cross, Michael ^[1]; Delaunois, Annie ^[3]; Dermody, Ailsa; Govindappa, Karthik ^[1]; Guillon, Jean-Michel ^[4]; Jenkins, Rosalind ^[1]; Kenna, Gerry ^[5]; Lemmer, Björn ^[6]; Meecham, Ken ^[7]; Olayanju, Adedamola ^[1]; Pestel, Sabine ^[8]; Rothfuss, Andreas ^[9] ; others, and

---

1. MRC Centre for Drug Safety Science, University of Liverpool (United Kingdom)
2. Lorraine University Pharmacolor Consultants Nancy PCN (France)
3. UCB Pharma (Belgium)
4. Sanofi-aventis (France)
5. Astra-Zeneca (United Kingdom)
6. Ruprecht-Karls-Universität Heidelberg (Germany)
7. Huntingdon Life Sciences (United Kingdom)
8. Boehringer-Ingelheim (Germany)
9. Roche (Switzerland)

Safety pharmacology (SP) is an essential part of the drug development process that aims to identify and predict adverse effects prior to clinical trials. SP studies are described in the International Conference on Harmonisation (ICH) S7A and S7B guidelines. The core battery and supplemental SP studies evaluate effects of a new chemical entity (NCE) at both anticipated therapeutic and supra-therapeutic exposures on major organ systems, including cardiovascular, central nervous, respiratory, renal and gastrointestinal. This review outlines the current practices and emerging concepts in SP studies including frontloading, parallel assessment of core battery studies, use of non-standard species, biomarkers, and combining toxicology and SP assessments. Integration of the newer approaches to routine SP studies may significantly enhance the scope of SP by refining and providing mechanistic insight to potential adverse effects associated with test compounds. - Highlights: • SP — mandatory non-clinical risk assessments performed during drug development. • SP organ system studies ensure the safety of clinical participants in FiH trials. • Frontloading in SP facilitates lead candidate drug selection. • Emerging trends: integrating SP-Toxicological endpoints; combined core battery tests.

• OSTI ID: 22285504
• Journal Information: Toxicology and Applied Pharmacology, Vol. 273, Issue 2; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0041-008X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
ALANINES
ALKALINE PHOSPHATASE
BIOLOGICAL MARKERS
CENTRAL NERVOUS SYSTEM
CLINICAL TRIALS
GLUTATHIONE
HEART
KIDNEYS
LACTATE DEHYDROGENASE
NEUTROPHILS
PHARMACOLOGY
RISK ASSESSMENT
SAFETY
STEM CELLS